Literature DB >> 7494284

Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments.

T Yamada1, C M Wheeler, A L Halpern, A C Stewart, A Hildesheim, S A Jenison.   

Abstract

Human papillomavirus type 16 (HPV16) nucleotide sequence variations in the E6 (nucleotide positions [nt] 104 to 559), L2 (nt 4272 to 5657), and L1 (nt 5665 to 7148) open reading frames (ORFs), and the long control region (nt 7479 to 7842), were examined in 29 selected United States isolates. Of 3,690 nucleotide positions, 129 (3.5%) varied. The maximum pairwise distance was 66 nucleotide differences, or 1.8%. Nucleotide variations within different genome segments were phylogenetically compatible, and nucleotide changes within E6, L2, and L1 contained phylogenetic information beyond that provided in the long control region. Most isolates were classified as members of HPV16 lineages that have been described previously. However, two novel phylogenetic branches were identified. The L2 ORF was the most variable coding segment. L2 synonymous and nonsynonymous nucleotide changes were distributed asymmetrically. The amino-terminal half of the L2 protein was remarkably conserved among all isolates, suggesting that the region is under evolutionary constraint. The amino-terminal region of the E6 ORF was relatively varied, especially at E6 amino acid positions 10 and 14. Several amino acid difference in the L1 ORF were observed between lineages. Forty-nine amino acid variations across all sequenced coding regions were observed. These amino acid differences may be relevant to differences in the generation of humoral or cell-mediated immune responses to HPV16 variants. Our data form a basis for considering HPV16 sequence variation in the rational design of vaccine strategies and as an epidemiologic correlate of cervical cancer risk.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494284      PMCID: PMC189716     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications.

Authors:  Q Chou; M Russell; D E Birch; J Raymond; W Bloch
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

2.  Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls.

Authors:  H G Köchel; M Monazahian; K Sievert; M Höhne; C Thomssen; A Teichmann; P Arendt; R Thomssen
Journal:  Int J Cancer       Date:  1991-07-09       Impact factor: 7.396

3.  A novel strategy for constructing clustered point mutations.

Authors:  M Haltiner; T Kempe; R Tjian
Journal:  Nucleic Acids Res       Date:  1985-02-11       Impact factor: 16.971

4.  Dideoxy sequencing method using denatured plasmid templates.

Authors:  M Hattori; Y Sakaki
Journal:  Anal Biochem       Date:  1986-02-01       Impact factor: 3.365

5.  Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16.

Authors:  J P Icenogle; P Sathya; D L Miller; R A Tucker; W E Rawls
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

6.  Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata.

Authors:  A Wikström; C Eklund; G Von Krogh; P Lidbrink; J Dillner
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16.

Authors:  D Eschle; M Dürst; J ter Meulen; J Luande; H C Eberhardt; M Pawlita; L Gissmann
Journal:  J Gen Virol       Date:  1992-07       Impact factor: 3.891

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Human papillomavirus type 16 DNA sequence.

Authors:  K Seedorf; G Krämmer; M Dürst; S Suhai; W G Röwekamp
Journal:  Virology       Date:  1985-08       Impact factor: 3.616

10.  Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind.

Authors:  S Y Chan; L Ho; C K Ong; V Chow; B Drescher; M Dürst; J ter Meulen; L Villa; J Luande; H N Mgaya
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  63 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  HPV genotype detection using hybrid capture sample preparation combined with whole genome amplification and multiplex detection with Luminex XMAP.

Authors:  Brian Lowe; Lori Kobayashi; Attila Lorincz; Rick Mallonee; Dominic O'Neil; Ha Thai; Irina Nazarenko
Journal:  J Mol Diagn       Date:  2010-09-16       Impact factor: 5.568

Review 3.  Human papillomavirus genome variants.

Authors:  Robert D Burk; Ariana Harari; Zigui Chen
Journal:  Virology       Date:  2013-08-31       Impact factor: 3.616

4.  Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.

Authors:  Rosemary E Zuna; William E Moore; Rebecca P Shanesmith; S Terence Dunn; Sophia S Wang; Mark Schiffman; Gregory L Blakey; Travis Teel
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

5.  Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective.

Authors:  T Yamada; M M Manos; J Peto; C E Greer; N Munoz; F X Bosch; C M Wheeler
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 6.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

7.  Primary structure of the cytosolic beta-glucosidase of guinea pig liver.

Authors:  W S Hays; S A Jenison; T Yamada; A Pastuszyn; R H Glew
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

8.  Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies.

Authors:  R Tachezy; I Mikysková; V Ludvíková; L Rob; T Kucera; V Slavík; A Beková; H Robová; M Pluta; E Hamsíková
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

9.  Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas.

Authors:  Andrew W Joseph; Takenori Ogawa; Justin A Bishop; Sofia Lyford-Pike; Xiaofei Chang; Timothy H Phelps; William H Westra; Sara I Pai
Journal:  Oral Oncol       Date:  2012-10-10       Impact factor: 5.337

10.  Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma.

Authors:  Yuri Agrawal; Wayne M Koch; Weihong Xiao; William H Westra; Anna L Trivett; David E Symer; Maura L Gillison
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.